In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study.

ABSTRACT:

Aims

Atrial fibrillation (AF) is a risk factor for brain infarction, which can lead to epilepsy. We aimed to investigate whether treatment of AF with direct oral anticoagulants (DOACs) affects the risk of epilepsy in comparison to treatment with the vitamin K antagonist phenprocoumon (PPC).

Methods and results

We performed an active comparator, nested case-control study based on the German Pharmacoepidemiological Research Database that includes claims data from statutory health insurance providers of about 25 million persons since 2004. In 2011-17, 227 707 AF patients initiated treatment with a DOAC or PPC, of which 1828 cases developed epilepsy on current treatment with an oral anticoagulant. They were matched to 19 084 controls without epilepsy. Patients with DOAC treatmen

SUBMITTER: Platzbecker K 

PROVIDER: S-EPMC10228540 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature